• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于比较测定药物制剂中依托考昔的毛细管区带电泳方法的验证

Validation of a capillary zone electrophoresis method for the comparative determination of etoricoxib in pharmaceutical formulations.

作者信息

Dalmora Sérgio Luiz, Sangoi Maximiliano da Silva, da Silva Lucélia Magalhães, Macedo Rui Oliveira, Barth Thiago

机构信息

Department of Industrial Pharmacy, Federal University of Santa Maria, Santa Maria, RS, Brazil.

出版信息

J Sep Sci. 2008 Jan;31(1):169-76. doi: 10.1002/jssc.200700272.

DOI:10.1002/jssc.200700272
PMID:18069701
Abstract

A CZE method was developed and validated for the analysis of etoricoxib in pharmaceutical dosage forms, using prilocaine as an internal standard. The CZE method was carried out on a fused-silica capillary (50 microm id, effective length 40 cm). The BGE consisted of 25 mM tris-phosphate solution at pH 2.5. The capillary temperature was maintained at 35 degrees C, the applied voltage was 25 kV, the injection was performed using the pressure mode at 50 mbar for 5 s, with detection at 234 nm using a photodiode array detector. The method was linear in the range of 2-150 microg/mL (r(2) = 0.9999). The specificity and stability-indicating capability were proven through the degradation studies and showing also that there was no interference of the excipients of the formulation. The accuracy was 99.49% with RSD of 0.66%. The limits of quantitation and detection were 2 and 0.58 microg/mL, respectively. Moreover, method validation demonstrated acceptable results for the precision, sensitivity, and robustness. The proposed method was successfully applied for the quantitative analysis of etoricoxib pharmaceutical formulations, and the results compared to the HPLC and LC-MS/MS methods, showing nonsignificant difference (p >0.05).

摘要

开发并验证了一种毛细管区带电泳(CZE)方法,用于分析药物剂型中的依托考昔,采用丙胺卡因作为内标。CZE方法在熔融石英毛细管(内径50μm,有效长度40cm)上进行。背景电解质(BGE)由pH 2.5的25mM磷酸三钠溶液组成。毛细管温度保持在35℃,施加电压为25kV,采用压力模式在50mbar下进样5s,使用光电二极管阵列检测器在234nm处进行检测。该方法在2-150μg/mL范围内呈线性(r(2)=0.9999)。通过降解研究证明了该方法的特异性和稳定性指示能力,并且还表明制剂辅料无干扰。准确度为99.49%,相对标准偏差(RSD)为0.66%。定量限和检测限分别为2和0.58μg/mL。此外,方法验证表明该方法在精密度、灵敏度和稳健性方面取得了可接受的结果。所提出的方法成功应用于依托考昔药物制剂的定量分析,结果与高效液相色谱(HPLC)和液相色谱-串联质谱(LC-MS/MS)方法相比,差异无统计学意义(p>0.05)。

相似文献

1
Validation of a capillary zone electrophoresis method for the comparative determination of etoricoxib in pharmaceutical formulations.用于比较测定药物制剂中依托考昔的毛细管区带电泳方法的验证
J Sep Sci. 2008 Jan;31(1):169-76. doi: 10.1002/jssc.200700272.
2
Determination of rupatadine in pharmaceutical formulations by a validated stability-indicating MEKC method.采用经验证的稳定性指示毛细管胶束电动色谱法测定药物制剂中的卢帕他定。
J Sep Sci. 2008 Sep;31(16-17):3098-105. doi: 10.1002/jssc.200800254.
3
Capillary zone electrophoresis for determination of vildagliptin (a DPP-4 inhibitor) in pharmaceutical formulation and comparative study with HPLC.毛细管区带电泳法测定药物制剂中维格列汀(一种二肽基肽酶-4抑制剂)及与高效液相色谱法的比较研究
Pharmazie. 2014 Feb;69(2):86-91.
4
Stability-indicating capillary zone electrophoresis method for the assessment of recombinant human interleukin-11 and its correlation with reversed-phase liquid chromatography and biossay.用于评估重组人白细胞介素-11的稳定性指示毛细管区带电泳法及其与反相液相色谱法和生物测定法的相关性。
Talanta. 2014 Jun;123:179-85. doi: 10.1016/j.talanta.2014.01.065. Epub 2014 Feb 20.
5
Validation of liquid chromatography and liquid chromatography/tandem mass spectrometry methods for the determination of etoricoxib in pharmaceutical formulations.液相色谱法和液相色谱/串联质谱法测定药物制剂中依托考昔的方法验证
J AOAC Int. 2006 Sep-Oct;89(5):1268-75.
6
Simultaneous analysis of biologically active pyridines in pharmaceutical formulations by capillary zone electrophoresis.通过毛细管区带电泳同时分析药物制剂中的生物活性吡啶。
J Chromatogr Sci. 2012 Feb;50(2):151-6. doi: 10.1093/chromsci/bmr037.
7
Optimisation, validation and application of a capillary electrophoretic method for the determination of zafirlukast in pharmaceutical formulations.一种用于测定药物制剂中扎鲁司特的毛细管电泳方法的优化、验证及应用
J Pharm Biomed Anal. 2007 May 9;44(1):16-22. doi: 10.1016/j.jpba.2007.01.008. Epub 2007 Jan 14.
8
Development and validation of a stability-indicating capillary zone electrophoretic method for the assessment of entecavir and its correlation with liquid chromatographic methods.用于评估恩替卡韦的稳定性指示毛细管区带电泳方法的开发与验证及其与液相色谱法的相关性
Anal Sci. 2011;27(3):265-70. doi: 10.2116/analsci.27.265.
9
Stability-indicating capillary zone electrophoresis method for the assessment of recombinant human granulocyte-macrophage colony-stimulating factor and its correlation with reversed-phase liquid chromatography method and bioassay.用于评估重组人粒细胞-巨噬细胞集落刺激因子的稳定性指示毛细管区带电泳法及其与反相液相色谱法和生物测定法的相关性。
Talanta. 2012 May 30;94:1-7. doi: 10.1016/j.talanta.2012.03.015. Epub 2012 Mar 11.
10
Purity assessment of recombinant human granulocyte colony-stimulating factor in finished drug product by capillary zone electrophoresis.采用毛细管区带电泳法对成品药物中重组人粒细胞集落刺激因子进行纯度评估。
Electrophoresis. 2014 Sep;35(18):2608-14. doi: 10.1002/elps.201300552. Epub 2014 Aug 1.

引用本文的文献

1
Fast and Sensitive HPLC-ESI-MS/MS Method for Etoricoxib Quantification in Human Plasma and Application to Bioequivalence Study.HPLC-ESI-MS/MS 法快速灵敏测定人血浆中依托考昔浓度及其用于生物等效性研究。
Molecules. 2022 Sep 4;27(17):5706. doi: 10.3390/molecules27175706.
2
Ionisable substances chromatography: A new approach for the determination of Ketoprofen, Etoricoxib, and Diclofenac sodium in pharmaceuticals using ion - pair HPLC.可离子化物质色谱法:一种使用离子对高效液相色谱法测定药物中酮洛芬、依托考昔和双氯芬酸钠的新方法。
Heliyon. 2020 Aug 4;6(8):e04613. doi: 10.1016/j.heliyon.2020.e04613. eCollection 2020 Aug.
3
A simple Ultraviolet spectrophotometric method for the determination of etoricoxib in dosage formulations.
一种用于测定剂型中依托考昔的简单紫外分光光度法。
J Adv Pharm Technol Res. 2012 Oct;3(4):237-40. doi: 10.4103/2231-4040.104715.
4
Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.依托考昔的临床药代动力学和药效学特征
Clin Pharmacokinet. 2008;47(11):703-20. doi: 10.2165/00003088-200847110-00002.